Tarsus Pharmaceuticals, Inc. (TARS) Tops Q4 EPS by 7c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($1.31), $0.07 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.08 million versus the consensus estimate of $5.29 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Culper Research short Tarsus Pharmaceuticals
• Exclusive: Moomoo to launch unified ’Moomoo Engine’ trading toolkit
• Kraken Robotics closes $615M Covelya acquisition, raises 2026 outlook